The authors concluded that in this study the combination of brostallicin and cisplatin was an active regimen in heavily pre-treated metastatic triple-negative breast cancer patients. A follow-up randomized Phase 2 trial using the reduced dosing regimen is in development.
The poster is available at
About Triple-Negative Breast Cancer
This term is used to describe breast cancers (usually invasive ductal carcinomas) whose cells lack estrogen and progesterone receptors, and do not express HER2. Breast cancers with these characteristics occur more often in younger women and African-American women. Triple-negative breast cancers are diagnosed at a later stage and spread more quickly than most other types of breast cancer. Because the tumor cells lack receptors, neither hormone therapy nor drugs that target HER2 are effective.
Patients with TNBC may respond to chemotherapy but responses are generally short and no therapy has been shown to be effective in patients who have more than one relapse.
About 10 to 20 percent of breast cancers are triple-negative.
Brostallicin, a novel synthetic second-generation DNA minor groove binder, has shown potent cancer killing activity, and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies, in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor groove, interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination studies.
About Cell Therapeutics, Inc.
Cell Therapeutics (Nasdaq and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in
For additional information and to sign up for email alerts and get RSS feeds, please visit
Safe Harbor Statement
This press release includes forward-looking statements that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of brostallicin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with brostallicin in particular, including, without limitation, the potential failure of brostallicin to prove safe and effective for the treatment of women with metastatic triple-negative breast cancer, either alone or in combination with cisplatin, as determined by the U.S. Food and Drug Administration and/or the European Medicines Agency; that additional clinical trials of brostallicin may not occur as planned; CTI's ability to continue to raise capital as needed to fund its operations; and competitive factors, technological developments, costs of developing, producing and selling CTI's product candidates, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.